Zhejiang Haisen Pharmaceutical Co Ltd
SZSE:001367
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (8.7), the stock would be worth ¥30.38 (28% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.8 | ¥23.7 |
0%
|
| 3-Year Average | 8.7 | ¥30.38 |
+28%
|
| 5-Year Average | 8.7 | ¥30.38 |
+28%
|
| Industry Average | 3.9 | ¥13.74 |
-42%
|
| Country Average | 2.8 | ¥9.65 |
-59%
|
Forward P/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
Z
|
Zhejiang Haisen Pharmaceutical Co Ltd
SZSE:001367
|
3.6B CNY | 6.8 | 26.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
910.2B USD | 14 | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 5.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 4.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 5 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 4.3 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 2.4 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.2B USD | 2.4 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.8 |
| 70th Percentile | 5.4 |
| Max | 5 034 353.9 |
Other Multiples
Zhejiang Haisen Pharmaceutical Co Ltd
Glance View
Zhejiang Haisen Pharmaceutical Co., Ltd. engages in the research, development, production, and sales of chemical raw materials and intermediates. The company is headquartered in Jinhua, Zhejiang. The company went IPO on 2023-04-10. The firm's main drugs include digestive system drugs, antipyretic and analgesic drugs, cardiovascular APIs, antidepressants drugs, antibacterial APIs, antiviral drugs, non-steroidal anti-inflammatory and other specialty APIs and preparations. The firm mainly conducts its businesses in domestic and overseas markets.
